Announcements Trials
Browse Landscape

Phase

Phase 1 7

Status

Completed 6Withdrawn 1

Sponsor Class

INDUSTRY 7

Study Type

Interventional 7

Sponsor

Cancer Type

Gastrointestinal 13Tumor-Agnostic 7Lymphoid 6Breast 6Other solid neoplasm 5Head & Neck 3Genitourinary 3Gynecologic 2Thoracic 1Other hematologic neoplasm 1Other 1Dermatologic 1

Conditions

Neoplasms 7

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Radiosurgery 27Blood Specimen Collection 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Interventional × Omeprazole × Tumor-Agnostic × Clear all
NCT02740712 2023-06-09

DDI

pharmaand GmbH

Phase 1 Completed
17 enrolled
Tumor-Agnostic

Neoplasms

NCT01596647 2020-12-21

Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors

Novartis

Phase 1 Completed
39 enrolled
Tumor-Agnostic

Neoplasms

NCT00420615 2020-12-08

Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies

Novartis

Phase 1 Completed
34 enrolled
Tumor-Agnostic

Neoplasms

NCT01287598 2019-07-10

BAY73-4506 Probe Substrate Study

Bayer

Phase 1 Completed
41 enrolled
Tumor-Agnostic

Neoplasms

NCT01517399 2019-02-12

Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects

Daiichi Sankyo

Phase 1 Completed
28 enrolled
Tumor-Agnostic

Neoplasms

NCT00442741 2012-04-25

Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies (Extension)

Novartis

Phase 1 Withdrawn
Tumor-Agnostic

Neoplasms

NCT00298779 2008-06-06

Open-Label Study to Assess the Effect of Omeprazole on the Pharmacokinetics of VELCADE in Patients With Either Advanced Solid Tumors or Non-Hodgkin's Lymphoma.

Millennium Pharmaceuticals, Inc.

Phase 1 Completed
20 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡